VIA SIGNATURE CONFIRMED DELIVERY

June 7, 2018

Masoud Rashidi, Owner/Pharmacy Manager
Innovative Compounding Pharmacy
820 Wales Drive, Suite 3
Folsom, CA 95630-5546

Dear Mr. Rashidi:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Innovative Compounding Pharmacy, located at 820 Wales Drive, Suite 3, Folsom, CA 95630-5546, from July 19, 2017, to July 28, 2017, by the U.S. Food and Drug Administration (FDA).

When the Agency concludes that an inspection is “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Maria Kelly-Doggett, Compliance Officer at (425) 302-0427 or Maria.Kelly-Doggett@fda.hhs.gov.

Sincerely,

CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

SP: mpk

Enclosure: EIR

Division of Pharmaceutical Quality Operations IV
19701 Fairchild, Irvine CA 92612-2506
Telephone: 949-608-2900
Fax: 949-608-4417
www.fda.gov